

1 YEAR REVIEW OF THE EKOSONIC® ENDOVASCULAR SYSTEM (BOSTON SCIENTIFIC) IN THE MANAGEMENT OF PULMONARY EMBOLISM IN AN INTERVENTIONAL CARDIOLOGY DEPARTMENT



E. MOGUEZ¹, C. GREZARD¹, P.POTIER³, A. GAMET², A. LEFRANÇOIS¹

¹DEPARTMENT OF PHARMACY, ORLEANS UNIVERSITY HOSPITAL, FRANCE

²DEPARTMENT OF CARDIOLOGY, ORLEANS UNIVERSITY HOSPITAL, FRANCE

³MEDICAL INFORMATION DEPARTMENT, ORLEANS UNIVERSITY HOSPITAL, FRANCE

emma.moguez@orange.fr

Background

Since September 2022 in the Orléans University Hospital

Use of the EkoS®

→ Percutaneously inserted thrombolysis catheter

→ Treatment for intermediate risk or severe pulmonary embolism (PE)


→ Enables in situ administration of Actilyse® (alteplase) + application of ultrasound

Goals: for all patients

→ To collect the indications of treated patients, the therapeutic protocol (TP)

→ To assess the financial impact of EkoS on their stays

Expensive medical device not currently reimbursed



📅 Period 09/2022 – 08/2023

🔍 Collect of indications, clinical contexts and TPs from patient records

📖 Literature review

💰 Cost analysis : Contact with the Medical Information Department (MID) to obtain Medical Program of Informatics Systems (MPIS) data

Methods

Results

Number of patients treated	6
Sex ratio M/F	4/2
Median age	69
Indication	High-intermediate risk bilateral pulmonary embolism
Number of catheters used per patient	2

TABLE 1: PATIENTS' CHARACTERISTICS

Therapeutic protocol used:
1 mg/h of Actilyse® per catheter for 6h
(Use of 2 vials of 10mg per patient)

Technique cost per patient (MD + Actilyse®):
6300€ excluding VAT (3000€/catheter + 150€/vial of Actilyse®)

The amount only covers the technique cost 😞

Coded main diagnosis	Related act	Average amount allocated per stay
PE with (2 patients) or without (4 patients) mention of pulmonary heart disease	None (4 patients) Fibrinolysis (2 patients)	6 453€ (includes the basic stay cost + intensive care package)

OPTIMIZED CODING

TABLE 2: INITIAL MPIS DATA

INTENSIVE CARE ADMISSION = PULMONARY HEART DISEASE
USE OF EKOS = FIBRINOLYSIS FOR ALL PATIENTS

Coded main diagnosis	Related act	Average amount allocated per stay
Heart failure + PE as associated diagnosis (6 patients)	Fibrinolysis (6 patients)	12 898€

TABLE 3: MPIS DATA OPTIMIZED



AMOUNT DOUBLED



STAY VALUATION

Conclusion



Used in accordance with the instructions from the manufacturer

→ The therapeutic protocol may evolve in line with new publications

At present, the amount allocated per stay covers only the technique cost

In the context of healthcare cost control, optimized coding will enable the continuous usage of this medical device in the future

Flowriver® (Inari), an innovative new DM used in the same indications and recently granted transitional approval, is likely to shake up management protocols

EkoS® use within the Orléans University Hospital

1ISG-021

